Nchi: Afrika Kusini
Lugha: Kiingereza
Chanzo: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
MODECATE INJECTION SCHEDULING STATUS: S5 PP ZIMBABWE ONLY PROPRIETARY NAME (and dosage form): MODECATE INJECTION COMPOSITION 25 mg Fluphenazine Decanoate per mL in sesame oil preserved with 1,5% m/v benzyl alcohol. PHARMACOLOGICAL CLASSIFICATION Category A 2.6.1 Phenothiazine and derivative. PHARMACOLOGICAL ACTION Fluphenazine decanoate is an esterified trifluoromethyl phenothiazine derivative. Its chemical name is 4-(3-[2- (trifluoromethyl)phenothiazin-10-yl]propyl)-1 piperazine. It is an antipsychotic agent with an extended duration of action. Fluphenazine has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown, but may be due to competitive antagonism of dopamine, some of its side effects can be ascribed to competitive antagonism of dopamine, and to blockade of alpha-adrenergic receptors or muscarinic receptors. Fluphenazine is extensively metabolised, undergoing "first pass" metabolism by the liver and is excreted in both the urine and faeces. It is highly protein-bound (>90%) in plasma. The serum half life is approximately 7-10 days. Fluphenazine crosses the blood-brain barrier, crosses the placenta easily and cannot be removed by dialysis. INDICATIONS MODECATE is indicated in the management of manifestations of psychotic disorders. It is of particular value in the treatment of chronic schizophrenia. It is not only useful in the hospital milieu, but is useful because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. CONTRA-INDICATIONS Patients with suspected or established parkinsonism. Phenothiazine compounds should not be used in patients receiving large doses of hypnotics. In comatose or Soma hati kamili